Experientia

, Volume 33, Issue 12, pp 1657–1659 | Cite as

Oxatomide, a new orally active drug which inhibits both the release and the effects of allergic mediators

  • F. Awouters
  • C. J. E. Niemegeers
  • J. Van den Berk
  • J. M. Van Nueten
  • F. M. Lenaerts
  • M. Borgers
  • K. H. L. Schellekens
  • A. Broeckaert
  • J. De Cree
  • P. A. J. Janssen
Specialia Haematologica, Immunologica

Summary

Oxatomide is a new potent inhibitor of anaphylactic and allergic reactions. After oral administration, the compound both inhibits the release of endogenous histamine and prevents the effects of exogenous histamine, at comparable doses. The combination of these effects appears to be the basis of the effectiveness of oxatomide in allergic reactions and may lead to clinical applications different from classical antihistaminics and from cromoglycate.

Keywords

Histamine Oral Administration Clinical Application Potent Inhibitor Allergic Reaction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    J. F. Riley and G. B. West, J. Physiol.120, 528 (1953). J. F. Riley and G. B. West, in: Histamine and antihistamines, p. 116. Ed. M. Rocha e Silva. Springer, New York 1966.PubMedGoogle Scholar
  2. 2.
    T. Ishizaka, C. S. Soto and K. Ishizaka, J. Immun.111, 500 (1973).PubMedGoogle Scholar
  3. 3.
    L. M. Lichtenstein and A. G. Osler, J. exp. Med.120, 507 (1964). W. E. Parish, Nature215, 738 (1967).PubMedGoogle Scholar
  4. 4.
    R. Patterson, J. M. Mc Kenna, I. M. Suszko, N. H. Solliday, J. J. Pruzansky, M. Roberts and T. J. Kehoe, J. clin. Invest.59, 217 (1977).PubMedGoogle Scholar
  5. 5.
    B. N. Halpern, Archs int. Pharmacodyn. Thér.68, 339 (1942).Google Scholar
  6. 6.
    D. S. Pearlman, Drugs12, 258 (1976).PubMedGoogle Scholar
  7. 7.
    E. F. Ellis, Postgrad. Med.59, 127 (1976). D. H. Goodman, Am. Fam. Physn11, 74 (1975).Google Scholar
  8. 8.
    J. S. G. Cox, Nature216, 1328 (1967).PubMedGoogle Scholar
  9. 9.
    F. Awouters, C. J. E. Niemegeers and P. A. J. Janssen, Archs int. Pharmacodyn. Thér.217, 38 (1975).Google Scholar
  10. 10.
    D. H. Bryant, M. W. Burns and L. Lazarus, J. Allergy clin. Immun.56, 417 (1975).PubMedGoogle Scholar
  11. 11.
    M. M. Portier and C. Richet, c. r. séanc. Soc. Biol.54, 170 (1902).Google Scholar
  12. 12.
    B. H. Booth, R. Patterson and C. H. Talbot, J. Lab. clin. Med.76, 181 (1970), M. Rocha e Silva and A. Graña, Archs Surg.52, 523 (1946).PubMedGoogle Scholar
  13. 13.
    W. Lorenz, Agents Actions5, 402 (1975).PubMedGoogle Scholar
  14. 14.
    R. P. Siraganian, J. Immun. Meth.7, 283 (1975).Google Scholar
  15. 15.
    M. Borgers, M. De Brabander, J. Van Reempts and F. Awouters, Lab. Invest.37, 1 (1977).PubMedGoogle Scholar
  16. 16.
    R. De Beule, E. Vannieuwenhuyse, J. Callier, W. Verstraete, F. Degreef, M. Gregoire, Y. Robience, W. Stevens and P. Libert, Acta allerg.32, 278 (1977).Google Scholar
  17. 17.
    J. De Cree, J. Streumer, H. Geukens and H. Verhaegen, submitted for publication (1977).Google Scholar

Copyright information

© Birkhäuser Verlag 1977

Authors and Affiliations

  • F. Awouters
    • 1
  • C. J. E. Niemegeers
    • 1
  • J. Van den Berk
    • 1
  • J. M. Van Nueten
    • 1
  • F. M. Lenaerts
    • 1
  • M. Borgers
    • 1
  • K. H. L. Schellekens
    • 1
  • A. Broeckaert
    • 1
  • J. De Cree
    • 1
  • P. A. J. Janssen
    • 1
  1. 1.Research LaboratoriaJanssen PharmaceuticaBeerseBelgium

Personalised recommendations